We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Rises But Trails Market: What Investors Should Know
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) closed the most recent trading day at $43.06, moving +0.14% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 1.18%. On the other hand, the Dow registered a gain of 0.87%, and the technology-centric Nasdaq increased by 1.6%.
Prior to today's trading, shares of the company had lost 12.85% over the past month. This has lagged the Medical sector's loss of 3.03% and the S&P 500's loss of 5.17% in that time.
Market participants will be closely following the financial results of CRISPR Therapeutics AG in its upcoming release. The company is expected to report EPS of -$1.83, up 18.3% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $20.52 million, up 22704.44% from the prior-year quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$4.97 per share and revenue of $271.03 million. These totals would mark changes of +40.55% and +22523.56%, respectively, from last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for CRISPR Therapeutics AG. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Currently, CRISPR Therapeutics AG is carrying a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 90, putting it in the top 36% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Rises But Trails Market: What Investors Should Know
CRISPR Therapeutics AG (CRSP - Free Report) closed the most recent trading day at $43.06, moving +0.14% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 1.18%. On the other hand, the Dow registered a gain of 0.87%, and the technology-centric Nasdaq increased by 1.6%.
Prior to today's trading, shares of the company had lost 12.85% over the past month. This has lagged the Medical sector's loss of 3.03% and the S&P 500's loss of 5.17% in that time.
Market participants will be closely following the financial results of CRISPR Therapeutics AG in its upcoming release. The company is expected to report EPS of -$1.83, up 18.3% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $20.52 million, up 22704.44% from the prior-year quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$4.97 per share and revenue of $271.03 million. These totals would mark changes of +40.55% and +22523.56%, respectively, from last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for CRISPR Therapeutics AG. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Currently, CRISPR Therapeutics AG is carrying a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 90, putting it in the top 36% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.